Hematologic Neoplastic Disorders
23 cases on [genuine one-line description of what this topic's real clinical territory covers] — choose a case below to open its full multi-voice debate.
A single patient newly diagnosed with chronic-phase CML, whose vascular tree has already failed once. Every drug that would treat his leukemia fastest carries the signal his femoral artery has the least room to absorb.
A single patient in sustained deep molecular response, asking to stop CML therapy for a second time after her first attempt failed. The disagreement isn't about whether TFR is ever appropriate for her — it's about how much weight her own prior failure should carry against a new, concrete reason to try again.
The guideline's first-choice cytoreductive agent for high-risk polycythemia vera has a characteristic toxicity, and it lands on exactly the tissue this patient spent five years getting to heal.
A single patient with newly diagnosed essential thrombocythemia who scores low risk on the standard thrombosis model. The disagreement isn't about the model's arithmetic — it's about what that model doesn't ask her.
Two patients with primary myelofibrosis, needing JAK-inhibitor therapy for the same underlying disease. The disagreement in each case is genuinely independent — not a shared debate split across two patients, but two cytopenia profiles pointing toward two different drugs.
Two induction regimens for high-risk APL, each of which will injure a 34-year-old's heart in a different decade. What nobody has yet established is whether her borderline QT is really hers or belongs to an uncorrected chemistry panel.
A single patient with newly diagnosed AML carrying a favorable molecular profile and early frailty markers at once. The disagreement isn't about the biology or the geriatric findings individually — it's about which one should set the pace of treatment.
Two men, the same higher-risk MDS diagnosis three weeks apart, the same complex karyotype. One argument is about the fortnight before a transplant everyone agrees on; the other is about whether a comorbidity index computed from a chart should be allowed to decide anything.
A single patient needing first-line CLL therapy, with atrial fibrillation and chronic kidney disease both genuinely relevant to the choice. The disagreement isn't which regimen is safe — neither cleanly is — it's which risk is more manageable to accept.
A single patient reaching maintenance therapy after autologous transplant for high-risk myeloma. The disagreement isn't about whether maintenance is needed — it's about whether his specific cytogenetics justify a more intensive, more toxic regimen than the post-transplant standard.
Two trials moved the second-line standard in early-relapse DLBCL to CAR-T, and this patient sits inside their enrolled population. She also sits outside the group whose outcomes generated the result.
A single patient with high-risk smoldering myeloma and no symptoms at all. The disagreement isn't about whether a new trial changed the evidence — it did — it's about whether that evidence answers the question that actually matters to him.
A 29-year-old guitarist with advanced Hodgkin lymphoma, choosing between a regimen that threatens his lungs and one that threatens his hands. Only one of those two organs has actually been measured.
A G6PD result takes the best tumor-lysis prophylaxis off the table absolutely, not conditionally. What is left has to be assembled from weaker components, and started before a rapidly growing lymphoma finishes making the decision for everyone.
A single patient with asymptomatic, low-burden follicular lymphoma who meets no criteria for treatment. The disagreement isn't about the survival evidence — both hematologists agree on it — it's about which of the same trial's real findings should guide her specific care.
A fit 68-year-old with favorable-biology mantle cell lymphoma, three years past the upper age limit of the trial that reshaped how this disease is treated — and inside the age range of a different trial that reached a weaker conclusion about the same drug.
A partial response at four months after H. pylori eradication is either a lymphoma still on its way out or a lymphoma that was never going to leave. A single translocation result separates those two readings — and it was run on tissue taken before treatment started.
A single patient with newly diagnosed, symptomatic Waldenström macroglobulinemia and pre-existing anticoagulation. The disagreement about his long-term regimen sits alongside, not instead of, an urgent problem that needs its own separate, immediate answer.
The drug that gave this patient three years of remission works partly by suppressing the marrow. He is pancytopenic before anyone has treated him this time.
A very good partial response to induction is the standard signal to proceed to transplant in myeloma, and much of the instinct to transplant this patient is borrowed from that setting. Her disease has infiltrated the organ that conditioning stresses most.
Two solid-organ transplant recipients who both developed PTLD. The disagreement in each case is genuinely independent — one about whether their own immune system, freed from suppression, deserves a real chance to clear the disease first; the other about whether that same chance is too slow for what's already in front of the team.
A label written for CD30-positive PTCL as a category, a trial whose result came overwhelmingly from one subtype, and a patient who belongs to a different one. Whichever regimen wins the argument, it will be delivering a neurotoxin to feet that diabetes has already damaged.
A single patient with DLBCL relapsed after CAR-T therapy. The disagreement isn't only about which drug is more effective — it's about whether a real-world access barrier settles the question before the efficacy debate needs to.